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Clostridium difficile infection is a rare precipitant of atypical haemolytic uraemic syndrome (aHUS). A 46-year-old man presented
with watery diarrhoea following an ileocaecal resection. He developed an acute kidney injury with anaemia, thrombocytopaenia,
raised lactate dehydrogenase, low haptoglobin, and red cell fragments. Stool sample was positive for C. difficile toxin B. He became
dialysis-dependent as his renal function continued to worsen despite treatment with empiric antibiotics and plasma exchange. The
ADAMTS13 level was normal consistent with a diagnosis of aHUS. The commencement of eculizumab led to the resolution of
haemolysis and stabilisation of haemoglobin and platelets with an improvement in renal function.
1. Background
Atypical haemolytic uraemic syndrome (aHUS) is a rare dis-
order characterised by thrombocytopaenia and evidence of
microangiopathic haemolysis. ADAMTS13 levels are normal
and STEC (Shiga toxin-producing E. coli) is not present in
the stool.Thepathogenesis involves activation of complement
via the alternative pathway leading to a thrombotic microan-
giopathy with end-organ involvement predominantly affect-
ing the renal and neurological systems [1]. The precipitants
for aHUS include complement regulation deficits, infections,
drugs, and pregnancy [2]. Clostridium difficile infection has
been identified as a rare precipitant [3–7].
2. Case Report
A 46-year-old man with no past medical history and no
regular medications presented to a rural hospital with an
acute abdomen. An explorative laparotomy revealed a small
bowel obstruction secondary to a congenital band with an
associated strangulated segment that required an ileocaecal
resection. The patient received antibiotic cover with cepha-
zolin, gentamicin, and metronidazole in addition to opioid
analgesia. On the tenth postoperative day he had watery
diarrhoea. On the following day the patient became anuric
with moderate hypertension (BP 160/80).
Blood tests revealed an acute kidney injury with a
sudden rise in creatinine from 71 to 307 𝜇mol/L (reference
range RR 50–120 𝜇mol/L). The blood film showed red cell
fragments (18–24 per HPF) together with an acute anaemia,
nadir haemoglobin 68 g/L (RR 110–150 g/L), and thrombo-
cytopaenia, nadir platelet count 87 × 109/L (RR 150–450 ×
109/L). Further blood tests revealed a lactate dehydrogenase
(LDH) of 1657 (RR 110–230U/L), a haptoglobin of 0.09 (RR
0.50–2.50), a bilirubin of 86 (RR 2–24), and a negative direct
antibody test (DAT). Complement components were low
with C3 of 0.75 (RR 0.85–1.60) and C4 of 0.09 (RR 0.12–0.36).
There was a coinciding derangement in the liver func-
tion tests with gamma-glutamyl transferase (GGT) 589 IU/L
(RR < 60 IU/L), alkaline phosphatase (ALP) 112 IU/L (RR
< 55 IU/L), aspartate transaminase (AST) 60 IU/L (RR <
55 IU/L), and alanine transaminase (ALT) 209 IU/l (RR <
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45 IU/L) which was attributed to critical illness.There was an
associated coagulopathy with INR 4.9 (range 0.9–1.2), APTT
67 (range 24–38), fibrinogen 3.0 (range 1.5–4), and D-dimer
3.2 that had likely resulted from the hepatic dysfunction.
The stool sample was positive for Clostridium difficile
toxin B and negative for Shiga toxin on two occasions. Stool
culture was negative for other enteric pathogens. ADAMTS13
activity was 69% which is within the normal reference
range. Autoimmune screen for ANA, dsDNA, and ANCA
was negative. Renal tract ultrasound revealed normal sized
kidneys with no hydronephrosis. Liver ultrasound showed
hepatomegaly (18 cm) with no evidence of biliary obstruc-
tion. Complement factor H (CFH) gene analysis did not
reveal a mutation.
The patient received daily plasma exchange and haemodi-
alysis in the Intensive Care Unit. Intravenous metronidazole
and oral vancomycin were given as antibiotic therapy for
C. difficile. Multiple blood transfusions were required to
maintain the haemoglobin. The patient required intubation
and ventilation for hypoxic respiratory failure for a period of
18 days.
Eculizumab infusions were commenced with the cessa-
tion of plasma exchange. The protocol involved infusions of
900mg weekly for four weeks followed by a single infusion of
1200mg in the fifth week. During the maintenance phase the
patient received fortnightly infusions of 1200mg for one year.
Eculizumab treatment led to a normalisation in haemo-
globin, platelet count, LDH, and haptoglobin over the follow-
ing fortnight. The patient then became dialysis-independent
and serum creatinine stabilised at 200 𝜇mol/L prior to dis-
charge.
He continued to receive eculizumab as an outpatient for
one year. There was no relapse of disease on eculizumab ces-
sation.He continues to bemonitoredwith regular blood tests.
His renal function remains stable at a new baseline creatinine
of 130 𝜇mol/L and there is no evidence of haemolysis.
3. Discussion
Atypical haemolytic uraemic syndrome is a clinical diagnosis
based onmicroangiopathic haemolytic anaemia, thrombocy-
topaenia, and acute kidney injury in the absence of STECwith
normal ADAMTS13 activity. Episodes may be precipitated
by infection in patients with a genetic susceptibility to
complement dysregulation. However, specific complement
gene pathway mutations are found in only 50–60% of cases
of true aHUS [8].
This case provides further evidence for C. difficile infec-
tion as a rare precipitant of aHUS. There are seven reported
adult cases of C. difficile-associated aHUS with this being
the first to occur in an adult male and following abdominal
surgery [3–7]. The characteristics of these cases are listed
in Table 1. While all cases have shared similar clinical
presentations of anaemia, thrombocytopaenia and acute
kidney injury, the nature of diarrhoea has varied with both
watery and bloody stools being reported. Confusion has
been reported in four of eight reported cases suggesting that
neurological involvement may occur. However, confusion
was not present in our case.
Various treatments have been used in the reported cases
of C. difficile-associated aHUS including antibiotics, steroids,
and plasma exchange with generally favourable outcomes
in all but one patient who developed allograft failure and
required graft nephrectomy [7]. There have been no docu-
mented recurrences of C. difficile-associated aHUS.
Terminal complement inhibitors have emerged as an
effective therapy for aHUS. Eculizumab has been shown
to control haemolysis and lead to improvements in renal
function [9]. This is the first reported case of C. difficile-
associated aHUS to be treated with eculizumab in addition
to conventional therapies. The patient responded favourably
with resolution of haemolysis, normalisation of haemoglobin
and platelets, and an improvement in renal function. There
has been no recurrence of disease two years after ceasing
eculizumab. Eculizumabmay be an effective agent for achiev-
ing resolution of haemolysis and stabilising renal function in
patients with C. difficile-associated aHUS.
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